Obesity, metabolic syndrome and diabetes mellitus after renal transplantation: Prevention and treatment

Transplantation Reviews

Volumn 28, Issue 2, 2014, Pages 37-46

  Wissing, Karl Martin ^a,b   Pipeleers, Lissa ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BELATACEPT; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOSPORIN; EVEROLIMUS; FATTY ACID; FLUINDOSTATIN; GLUCAGON LIKE PEPTIDE 1; IMMUNOSUPPRESSIVE AGENT; INSULIN; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MEGLITINIDE; METFORMIN; PIOGLITAZONE; RAPAMYCIN; ROSIGLITAZONE; SULFONYLUREA; TACROLIMUS;

BARIATRIC SURGERY; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; EXERCISE; GRAFT RECIPIENT; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN TREATMENT; INTRAABDOMINAL FAT; KIDNEY TRANSPLANTATION; LIFESTYLE MODIFICATION; LOW CALORY DIET; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NEW ONSET DIABETES AFTER TRANSPLANTATION; OBESITY; PATHOGENESIS; PHYSICAL ACTIVITY; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; REVIEW; SURGICAL RISK; TREATMENT OUTCOME; WEIGHT REDUCTION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; KIDNEY FAILURE, CHRONIC; MALE; MULTIMODALITY CANCER THERAPY; PRIMARY PREVENTION; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

ADRENAL CORTEX HORMONES; COMBINED MODALITY THERAPY; DIABETES MELLITUS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; METABOLIC SYNDROME X; OBESITY; PRIMARY PREVENTION; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84897105601     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2013.12.004     Document Type: Review

References (178)

1. Ojo A.O. Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006, 82:603-611.
2. Jardine A.G., Gaston R.S., Fellstrom B.C., Holdaas H. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet 2011, 378:1419-1427.
3. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
4. Alberti K.G., Zimmet P., Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006, 23:469-480.
5. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet 2005, 365:1415-1428.
6. Festa A., D'Agostino R., Howard G., Mykkanen L., Tracy R.P., Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 102:42-47.
7. Ridker P.M., Buring J.E., Cook N.R., Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003, 107:391-397.
8. Rutter M.K., Meigs J.B., Sullivan L.M., D'Agostino R.B., Wilson P.W. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004, 110:380-385.
9. Pradhan A.D., Manson J.E., Rifai N., Buring J.E., Ridker P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334.
10. Kuczmarski R.J., Flegal K.M., Campbell S.M., Johnson C.L. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA 1994, 272:205-211. [%20].
11. Ogden C.L., Carroll M.D., Curtin L.R., McDowell M.A., Tabak C.J., Flegal K.M. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006, 295:1549-1555.
12. Finucane M.M., Stevens G.A., Cowan M.J., et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011, 377:557-567.
13. Danaei G., Finucane M.M., Lu Y., et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011, 378:31-40.
14. Schold J.D., Srinivas T.R., Guerra G., et al. A "weight-listing" paradox for candidates of renal transplantation?. Am J Transplant 2007, 7:550-559.
15. van Raalte D.H., Ouwens D.M., Diamant M. Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options?. Eur J Clin Invest 2009, 39:81-93.
16. Knight S.R., Morris P.J. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 2010, 89:1-14.
17. Curtis J.R., Westfall A.O., Allison J., et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 2006, 55:420-426.
18. Da Silva J.A., Jacobs J.W., Kirwan J.R., et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 2006, 65:285-293.
19. Kasiske B.L., de Mattos A., Flechner S.M., et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 2008, 8:1384-1392.
20. Hoogeveen R.C., Ballantyne C.M., Pownall H.J., et al. Effect of sirolimus on the metabolism of apoB100- containing lipoproteins in renal transplant patients. Transplantation 2001, 72:1244-1250.
21. Ma K.L., Ruan X.Z., Powis S.H., Chen Y., Moorhead J.F., Varghese Z. Sirolimus modifies cholesterol homeostasis in hepatic cells: a potential molecular mechanism for sirolimus-associated dyslipidemia. Transplantation 2007, 84:1029-1036.
22. Morrisett J.D., Abdel-Fattah G., Hoogeveen R., et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 2002, 43:1170-1180.
23. Di P.S., Teutonico A., Leogrande D., Capobianco C., Schena P.F. Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: a crossroad between cancer and diabetes?. J Am Soc Nephrol 2006, 17:2236-2244.
24. Teutonico A., Schena P.F., Di Paolo P.S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005, 16:3128-3135.
25. Johnston O., Rose C.L., Webster A.C., Gill J.S. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008, 19:1411-1418.
26. Roland M., Gatault P., Doute C., et al. Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantation. Transpl Int 2008, 21:523-530.
27. Ghisdal L., Baron C., Le Meur Y., et al. TCF7L2 polymorphism associates with new-onset diabetes after transplantation. J Am Soc Nephrol 2009, 20:2459-2467.
28. Ekberg H., Tedesco-Silva H., Demirbas A., et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007, 357:2562-2575. [%20].
29. Van Laecke L.S., Van Biesen B.W., Verbeke F., De Bacquer B.D., Peeters P., Vanholder R. Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation. Am J Transplant 2009, 9:2140-2149.
30. Roland M., Gatault P., Al-Najjar A., et al. Early pulse pressure and low-grade proteinuria as independent long-term risk factors for new-onset diabetes mellitus after kidney transplantation. Am J Transplant 2008, 8:1719-1728.
31. Fraenkel M., Ketzinel-Gilad M., Ariav Y., et al. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 2008, 57:945-957.
32. Artz M.A., Boots J.M., Ligtenberg G., et al. Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. J Am Soc Nephrol 2003, 14:1880-1888.
33. Wissing K.M., Unger P., Ghisdal L., et al. Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation. Transplantation 2006, 82:771-778.
34. McCune T.R., Thacker L.R., Peters T.G., et al. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study. Transplantation 1998, 65:87-92.
35. Ligtenberg G., Hene R.J., Blankestijn P.J., Koomans H.A. Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. J Am Soc Nephrol 2001, 12:368-373.
36. Vanrenterghem Y., Bresnahan B., Campistol J., et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation 2011, 91:976-983.
37. Miller L.W. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2002, 2:807-818.
38. Heit J.J., Apelqvist A.A., Gu X., et al. Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. Nature 2006, 443:345-349.
39. Tamura K., Fujimura T., Tsutsumi T., et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell. Transplantation 1995, 59:1606-1613.
40. Filler G., Neuschulz I., Vollmer I., Amendt P., Hocher B. Tacrolimus reversibly reduces insulin secretion in paediatric renal transplant recipients. Nephrol Dial Transplant 2000, 15:867-871.
41. Boots J.M., van Duijnhoven E.M., Christiaans M.H., Wolffenbuttel B.H., van Hooff J.P. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 2002, 13:221-227.
42. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
43. Ducloux D., Kazory A., Simula-Faivre D., Chalopin J.M. One-year post-transplant weight gain is a risk factor for graft loss. Am J Transplant 2005, 5:2922-2928.
44. Porrini E., Delgado P., Bigo C., et al. Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation. Am J Kidney Dis 2006, 48:134-142.
45. de Vries A.P., Bakker S.J., van Son W.J., et al. Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant 2004, 4:1675-1683.
46. Bayer N.D., Cochetti P.T., Anil Kumar M.S., et al. Association of metabolic syndrome with development of new-onset diabetes after transplantation. Transplantation 2010, 90:861-866.
47. Courivaud C., Kazory A., Simula-Faivre D., Chalopin J.M., Ducloux D. Metabolic syndrome and atherosclerotic events in renal transplant recipients. Transplantation 2007, 83:1577-1581.
48. Sharif A., Ravindran V., Dunseath G., Luzio S., Owens D.R., Baboolal K. Comparison of rival metabolic syndrome classifications against pathophysiological markers in renal transplant recipients. Transplantation 2010, 89:347-352.
49. Gore J.L., Pham P.T., Danovitch G.M., et al. Obesity and outcome following renal transplantation. Am J Transplant 2006, 6:357-363.
50. Molnar M.Z., Kovesdy C.P., Mucsi I., et al. Higher recipient body mass index is associated with post-transplant delayed kidney graft function. Kidney Int 2011, 80:218-224.
51. Meier-Kriesche H.U., Arndorfer J.A., Kaplan B. The impact of body mass index on renal transplant outcomes: a significant independent risk factor for graft failure and patient death. Transplantation 2002, 73:70-74.
52. Armstrong K.A., Campbell S.B., Hawley C.M., Nicol D.L., Johnson D.W., Isbel N.M. Obesity is associated with worsening cardiovascular risk factor profiles and proteinuria progression in renal transplant recipients. Am J Transplant 2005, 5:2710-2718.
53. Bosma R.J., Kwakernaak A.J., van der Heide J.J., de Jong P.E., Navis G.J. Body mass index and glomerular hyperfiltration in renal transplant recipients: cross-sectional analysis and long-term impact. Am J Transplant 2007, 7:645-652.
54. Israni A.K., Snyder J.J., Skeans M.A., Kasiske B.L. Clinical diagnosis of metabolic syndrome: predicting new-onset diabetes, coronary heart disease, and allograft failure late after kidney transplant. Transpl Int 2012, 25:748-757.
55. Kovesdy C.P., Czira M.E., Rudas A., et al. Body mass index, waist circumference and mortality in kidney transplant recipients. Am J Transplant 2010, 10:2644-2651.
56. Porrini E., Delgado P., Alvarez A., et al. The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation. Nephrol Dial Transplant 2008, 23:1436-1441.
57. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009, 9:S1-S155. 10.1111/j.1600-6143.2009.02834.x.:S1-155.
58. Armstrong K., Rakhit D., Jeffriess L., et al. Cardiorespiratory fitness is related to physical inactivity, metabolic risk factors, and atherosclerotic burden in glucose-intolerant renal transplant recipients. Clin J Am Soc Nephrol 2006, 1:1275-1283.
59. Zelle D.M., Corpeleijn E., Stolk R.P., et al. Low physical activity and risk of cardiovascular and all-cause mortality in renal transplant recipients. Clin J Am Soc Nephrol 2011, 6:898-905.
60. Orazio L., Hickman I., Armstrong K., Johnson D., Banks M., Isbel N. Higher levels of physical activity are associated with a lower risk of abnormal glucose tolerance in renal transplant recipients. J Ren Nutr 2009, 19:304-313.
61. van den Ham E.C., Kooman J.P., Schols A.M., et al. Similarities in skeletal muscle strength and exercise capacity between renal transplant and hemodialysis patients. Am J Transplant 2005, 5:1957-1965.
62. van den Ham E.C., Kooman J.P., Christiaans M.H., van Hooff J.P. Relation between steroid dose, body composition and physical activity in renal transplant patients. Transplantation 2000, 69:1591-1598.
63. Jennings G., Nelson L., Nestel P., et al. The effects of changes in physical activity on major cardiovascular risk factors, hemodynamics, sympathetic function, and glucose utilization in man: a controlled study of four levels of activity. Circulation 1986, 73:30-40.
64. Hu F.B., Stampfer M.J., Colditz G.A., et al. Physical activity and risk of stroke in women. JAMA 2000, 283:2961-2967.
65. Paffenbarger R.S., Hyde R.T., Wing A.L., Lee I.M., Jung D.L., Kampert J.B. The association of changes in physical-activity level and other lifestyle characteristics with mortality among men. N Engl J Med 1993, 328:538-545.
66. Leitzmann M.F., Park Y., Blair A., et al. Physical activity recommendations and decreased risk of mortality. Arch Intern Med 2007, 167:2453-2460.
67. Beddhu S., Baird B.C., Zitterkoph J., Neilson J., Greene T. Physical activity and mortality in chronic kidney disease (NHANES III). Clin J Am Soc Nephrol 2009, 4:1901-1906.
68. Painter P.L., Hector L., Ray K., et al. Effects of exercise training on coronary heart disease risk factors in renal transplant recipients. Am J Kidney Dis 2003, 42:362-369.
69. Painter P.L., Hector L., Ray K., et al. A randomized trial of exercise training after renal transplantation. Transplantation 2002, 74:42-48.
70. Patel M.G. The effect of dietary intervention on weight gains after renal transplantation. J Ren Nutr 1998, 8:137-141.
71. Lopes I.M., Martin M., Errasti P., Martinez J.A. Benefits of a dietary intervention on weight loss, body composition, and lipid profile after renal transplantation. Nutrition 1999, 15:7-10.
72. Li Z., Maglione M., Tu W., et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005, 142:532-546.
73. Barbaro D., Orsini P., Pallini S., Piazza F., Pasquini C. Obesity in transplant patients: case report showing interference of orlistat with absorption of cyclosporine and review of literature. Endocr Pract 2002, 8:124-126.
74. Buchwald H., Avidor Y., Braunwald E., et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004, 292:1724-1737.
75. Maggard M.A., Shugarman L.R., Suttorp M., et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med 2005, 142:547-559.
76. Sjostrom L., Lindroos A.K., Peltonen M., et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004, 351:2683-2693.
77. Sjostrom L., Narbro K., Sjostrom C.D., et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007, 357:741-752.
78. Adams T.D., Gress R.E., Smith S.C., et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007, 357:753-761.
79. Modanlou K.A., Muthyala U., Xiao H., et al. Bariatric surgery among kidney transplant candidates and recipients: analysis of the United States renal data system and literature review. Transplantation 2009, 87:1167-1173.
80. Glanton C.W., Kao T.C., Cruess D., Agodoa L.Y., Abbott K.C. Impact of renal transplantation on survival in end-stage renal disease patients with elevated body mass index. Kidney Int 2003, 63:647-653.
81. Segev D.L., Simpkins C.E., Thompson R.E., Locke J.E., Warren D.S., Montgomery R.A. Obesity impacts access to kidney transplantation. J Am Soc Nephrol 2008, 19:349-355.
82. Lentine K.L., Delos S.R., Axelrod D., Schnitzler M.A., Brennan D.C., Tuttle-Newhall J.E. Obesity and kidney transplant candidates: how big is too big for transplantation?. Am J Nephrol 2012, 36:575-586.
83. Khwaja A., El-Nahas M. Transplantation in the obese: separating myth from reality. Nephrol Dial Transplant 2012, 27:3732-3735.
84. Froeder L., Arasaki C.H., Malheiros C.A., Baxmann A.C., Heilberg I.P. Response to dietary oxalate after bariatric surgery. Clin J Am Soc Nephrol 2012, 7:2033-2040.
85. Nelson W.K., Houghton S.G., Milliner D.S., Lieske J.C., Sarr M.G. Enteric hyperoxaluria, nephrolithiasis, and oxalate nephropathy: potentially serious and unappreciated complications of Roux-en-Y gastric bypass. Surg Obes Relat Dis 2005, 1:481-485.
86. Sinha M.K., Collazo-Clavell M.L., Rule A., et al. Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery. Kidney Int 2007, 72:100-107.
87. Lieske J.C., Kumar R., Collazo-Clavell M.L. Nephrolithiasis after bariatric surgery for obesity. Semin Nephrol 2008, 28:163-173.
88. Kleinman J.G. Bariatric surgery, hyperoxaluria, and nephrolithiasis: a plea for close postoperative management of risk factors. Kidney Int 2007, 72:8-10.
89. Matlaga B.R., Shore A.D., Magnuson T., Clark J.M., Johns R., Makary M.A. Effect of gastric bypass surgery on kidney stone disease. J Urol 2009, 181:2573-2577.
90. Asselman M., Verhulst A., De Broe M.E., Verkoelen C.F. Calcium oxalate crystal adherence to hyaluronan-, osteopontin-, and CD44-expressing injured/regenerating tubular epithelial cells in rat kidneys. J Am Soc Nephrol 2003, 14:3155-3166.
91. Verhulst A., Asselman M., Persy V.P., et al. Crystal retention capacity of cells in the human nephron: involvement of CD44 and its ligands hyaluronic acid and osteopontin in the transition of a crystal binding- into a nonadherent epithelium. J Am Soc Nephrol 2003, 14:107-115.
92. Nasr S.H., D'Agati V.D., Said S.M., et al. Oxalate nephropathy complicating Roux-en-Y gastric bypass: an underrecognized cause of irreversible renal failure. Clin J Am Soc Nephrol 2008, 3:1676-1683.
93. Ahmed M.H., Byrne C.D. Bariatric surgery and renal function: a precarious balance between benefit and harm. Nephrol Dial Transplant 2010, 25:3142-3147.
94. Lefaucheur C., Hill G.S., Amrein C., et al. Acute oxalate nephropathy: a new etiology for acute renal failure following nonrenal solid organ transplantation. Am J Transplant 2006, 6:2516-2521.
95. Farese S., Trost N., Candinas D., Huynh-Do U. Early renal failure after domino hepatic transplantation using the liver from a compound heterozygous patient with primary hyperoxaluria. Nephrol Dial Transplant 2005, 20:2557-2560.
96. Donckier V., El Nakadi I., Closset J., et al. Domino hepatic transplantation using the liver from a patient with primary hyperoxaluria. Transplantation 2001, 71:1346-1348.
97. Pinheiro H.S., Camara N.O., Osaki K.S., De Moura L.A., Pacheco-Silva A. Early presence of calcium oxalate deposition in kidney graft biopsies is associated with poor long-term graft survival. Am J Transplant 2005, 5:323-329.
98. Vincenti F., Friman S., Scheuermann E., et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007, 7:1506-1514.
99. Kasiske B.L., Snyder J.J., Gilbertson D., Matas A.J. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003, 3:178-185.
100. Ghisdal L., Van L.S., Abramowicz M.J., Vanholder R., Abramowicz D. New-onset diabetes after renal transplantation: risk assessment and management. Diabetes Care 2012, 35:181-188.
101. Kamar N., Mariat C., Delahousse M., et al. Diabetes mellitus after kidney transplantation: a French multicentre observational study. Nephrol Dial Transplant 2007, 22:1986-1993.
102. Bloom R.D., Rao V., Weng F., Grossman R.A., Cohen D., Mange K.C. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 2002, 13:1374-1380.
103. Yang J., Hutchinson I.I., Shah T., Min D.I. Genetic and clinical risk factors of new-onset diabetes after transplantation in Hispanic kidney transplant recipients. Transplantation 2011, 91:1114-1119.
104. Hjelmesaeth J., Hartmann A., Leivestad T., et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006, 69:588-595.
105. Cole E.H., Johnston O., Rose C.L., Gill J.S. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol 2008, 3:814-821.
106. Burroughs T.E., Swindle J., Takemoto S., et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. Transplantation 2007, 83:1027-1034.
107. Gerstein H.C., Miller M.E., Byington R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559.
108. Gerstein H.C., Miller M.E., Genuth S., et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011, 364:818-828.
109. Patel A., MacMahon S., Chalmers J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
110. Inzucchi S.E., Bergenstal R.M., Buse J.B., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379.
111. Luan F.L., Steffick D.E., Ojo A.O. New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. Transplantation 2011, 91:334-341.
112. Anil Kumar M.S., Heifets M., Fyfe B., et al. Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy. Transplantation 2005, 80:807-814.
113. Boots J.M., Christiaans M.H., van Duijnhoven E.M., Van Suylen R.J., van Hooff J.P. Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. Transplantation 2002, 74:1703-1709.
114. Rostaing L., Cantarovich D., Mourad G., et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005, 79:807-814.
115. Pascual J., Royuela A., Galeano C., Crespo M., Zamora J. Very early steroid withdrawal or complete avoidance for kidney transplant recipients: a systematic review. Nephrol Dial Transplant 2012, 27:825-832.
116. Pascual J., Galeano C., Royuela A., Zamora J. A systematic review on steroid withdrawal between 3 and 6 months after kidney transplantation. Transplantation 2010, 90:343-349.
117. Hricik D.E., Bartucci M.R., Moir E.J., Mayes J.T., Schulak J.A. Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation 1991, 51:374-377.
118. Woodward R.S., Schnitzler M.A., Baty J., et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003, 3:590-598.
119. Heisel O., Heisel R., Balshaw R., Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004, 4:583-595.
120. Silva H.T., Yang H.C., Abouljoud M., et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 2007, 7:595-608.
121. Woodward R.S., Kutinova A., Schnitzler M.A., Brennan D.C. Renal graft survival and calcineurin inhibitor. Transplantation 2005, 80:629-633.
122. Bunnapradist S., Daswani A., Takemoto S.K. Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids. Transplantation 2003, 76:10-15.
123. Ghisdal L., Bouchta N.B., Broeders N., et al. Conversion from tacrolimus to cyclosporine A for new-onset diabetes after transplantation: a single-centre experience in renal transplanted patients and review of the literature. Transpl Int 2008, 21:146-151.
124. Ramos-Cebrian M., Torregrosa J.V., Gutierrez-Dalmau A., Oppenheimer F., Campistol J.M. Conversion from tacrolimus to cyclosporine could improve control of posttransplant diabetes mellitus after renal transplantation. Transplant Proc 2007, 39:2251-2253.
125. Lorho R., Hardwigsen J., Dumortier J., et al. Regression of new-onset diabetes mellitus after conversion from tacrolimus to cyclosporine in liver transplant patients: results of a pilot study. Clin Res Hepatol Gastroenterol 2011, 35:482-488.
126. Oberholzer J., Thielke J., Hatipoglu B., Testa G., Sankary H.N., Benedetti E. Immediate conversion from tacrolimus to cyclosporine in the treatment of posttransplantation diabetes mellitus. Transplant Proc 2005, 37:999-1000.
127. Dumortier J., Bernard S., Bouffard Y., Boillot O. Conversion from tacrolimus to cyclosporine in liver transplanted patients with diabetes mellitus. Liver Transpl 2006, 12:659-664.
128. Vincenti F., Charpentier B., Vanrenterghem Y., et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010, 10:535-546.
129. Durrbach A., Pestana J.M., Pearson T., et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010, 10:547-557.
130. Ferguson R., Grinyo J., Vincenti F., et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am J Transplant 2011, 11:66-76.
131. Fellstrom B., Jardine A.G., Soveri I., et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. Am J Transplant 2005, 5:1986-1991.
132. Meier-Kriesche H.U., Baliga R., Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003, 75:1291-1295.
133. Wilkinson A., Davidson J., Dotta F., et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 2005, 19:291-298.
134. Sharif A. Should metformin be our antiglycemic agent of choice post-transplantation?. Am J Transplant 2011, 11:1376-1381.
135. Lipska K.J., Bailey C.J., Inzucchi S.E. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011, 34:1431-1437.
136. Therasse A., Wallia A., Molitch M.E. Management of post-transplant diabetes. Curr Diab Rep 2013, 13:121-129.
137. Nissen S.E., Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010, 170:1191-1201.
138. Lovshin J.A., Drucker D.J. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009, 5:262-269.
139. Werzowa J., Hecking M., Haidinger M., et al. Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial. Transplantation 2013, 95:456-462.
140. Lane J.T., Odegaard D.E., Haire C.E., Collier D.S., Wrenshall L.E., Stevens R.B. Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation. Transplantation 2011, 92:e56-e57.
141. Kasiske B., Cosio F.G., Beto J., et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 2004, 4:13-53. [13-53].
142. Kasiske B.L., Chakkera H.A., Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000, 11:1735-1743.
143. Aakhus S., Dahl K., Wideroe T.E. Cardiovascular morbidity and risk factors in renal transplant patients. Nephrol Dial Transplant 1999, 14:648-654.
144. Jardine A.G., Fellstrom B., Logan J.O., et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. Am J Kidney Dis 2005, 46:529-536.
145. Mihaylova B., Emberson J., Blackwell L., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380:581-590.
146. Sever P.S., Dahlof B., Poulter N.R., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled tria. Lancet 2003, 361:1149-1158.
147. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
148. Holdaas H., Fellstrom B., Jardine A.G., et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003, 361:2024-2031.
149. Holdaas H., Fellstrom B., Cole E., et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 2005, 5:2929-2936.
150. Baigent C., Landray M.J., Reith C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011, 377:2181-2192.
151. Ichimaru N., Takahara S., Kokado Y., et al. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. Atherosclerosis 2001, 158:417-423.
152. Asberg A., Hartmann A., Fjeldsa E., Bergan S., Holdaas H. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transplant 2001, 1:382-386.
153. Lemahieu W.P., Hermann M., Asberg A., et al. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. Am J Transplant 2005, 5:2236-2243.
154. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) 2001, 285:2486-2497.
155. Grundy S.M., Vega G.L., Yuan Z., Battisti W.P., Brady W.E., Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005, 95:462-468.
156. Bays H.E., Dujovne C.A., McGovern M.E., et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol 2003, 91:667-672.
157. Broeders N., Knoop C., Antoine M., Tielemans C., Abramowicz D. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?. Nephrol Dial Transplant 2000, 15:1993-1999.
158. Hottelart C., El E.N., Rose F., Achard J.M., Fournier A. Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 2002, 92:536-541.
159. Forsblom C., Hiukka A., Leinonen E.S., Sundvall J., Groop P.H., Taskinen M.R. Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy. Diabetes Care 2010, 33:215-220.
160. Westphal S., Dierkes J., Luley C. Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet 2001, 358:39-40.
161. Ansquer J.C., Dalton R.N., Causse E., Crimet D., Le M.K., Foucher C. Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people. Am J Kidney Dis 2008, 51:904-913.
162. Mychaleckyj J.C., Craven T., Nayak U., et al. Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care 2012, 35:1008-1014.
163. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.
164. Ledwith B.J., Pauley C.J., Wagner L.K., Rokos C.L., Alberts D.W., Manam S. Induction of cyclooxygenase-2 expression by peroxisome proliferators and non-tetradecanoylphorbol 12,13-myristate-type tumor promoters in immortalized mouse liver cells. J Biol Chem 1997, 272:3707-3714.
165. Yoshinari M., Asano T., Kaori S., et al. Effect of gemfibrozil on serum levels of prostacyclin and precursor fatty acids in hyperlipidemic patients with Type 2 diabetes. Diabetes Res Clin Pract 1998, 42:149-154.
166. Franssen R., Vergeer M., Stroes E.S., Kastelein J.J. Combination statin-fibrate therapy: safety aspects. Diabetes Obes Metab 2009, 11:89-94.
167. Jones P.H., Davidson M.H. Reporting rate ofrhabdomyolysis with fenofibrate+statin versus gemfibrozil+any statin. Am J Cardiol 2005, 95:120-122.
168. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
169. Ginsberg H.N., Elam M.B., Lovato L.C., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563-1574.
170. Ballantyne C.M., Houri J., Notarbartolo A., et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003, 107:2409-2415. [%20].
171. Buchanan C., Smith L., Corbett J., Nelson E., Shihab F. A retrospective analysis of ezetimibe treatment in renal transplant recipients. Am J Transplant 2006, 6:770-774.
172. Kohnle M., Pietruck F., Kribben A., Philipp T., Heemann U., Witzke O. Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. Am J Transplant 2006, 6:205-208.
173. Boden W.E., Probstfield J.L., Anderson T., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011, 365:2255-2267.
174. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013, 34:1279-1291.
175. Anavekar N.S., McMurray J.J., Velazquez E.J., et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004, 351:1285-1295.
176. Soveri I., Holdaas H., Jardine A., Gimpelewicz C., Staffler B., Fellstrom B. Renal transplant dysfunction-importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality. Nephrol Dial Transplant 2006, 21:2282-2289.
177. Moranne O., Maillard N., Fafin C., Thibaudin L., Alamartine E., Mariat C. Rate of renal graft function decline after one year is a strong predictor of all-cause mortality. Am J Transplant 2013, 13:695-706.
178. Kaplan B., Meier-Kriesche H.U. Death after graft loss: an important late study endpoint in kidney transplantation. Am J Transplant 2002, 2:970-974.